MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04669namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250223033211.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
231126s2022 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
618.92994 |
| Edition number |
21 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
618.92994 |
| Edition number |
21 |
| 097 ## - Thesis Degree |
|---|
| Thesis Level |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Classification number |
Cai01.19.05.M.Sc.2022.Mu.E |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Muhammad Ahmed Muhammad al-sabagh, |
| Relator term |
preparation. |
| 245 14 - TITLE STATEMENT |
|---|
| Title |
The expression of CD79a in B-cell acute lymphoblastic leukemia (all) and its effect on the outcome / |
| Statement of responsibility, etc. |
by Muhammad Ahmed Muhammad Alsabagh ; supervisors Asmaa Mohamed Hamoda, Eman Zaghloul Kandeel, Sally Talaat Khattab. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
التأثير التعبير الأولى ل (سي دى 79 الفا ) على نتائج علاج سرطان الدم اليمفاوي من نوع الخلايا (ب) في الأطفال |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2022. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xii, 111 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.)-Cairo University, 2022. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 89-101. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Central nervous system (CNS) involvement is<br/>a challenge in diagnosis & treatment. Diagnosis and treatment of central<br/>nervous system (CNS) infiltration and/or CNS relapse in childhood acute<br/>lymphoblastic leukemia (ALL) remain challenging. CNS leukemia is mainly<br/>a leptomeningeal disease, but leukemic cells may be detectable in the<br/>cerebrospinal fluid.The study aimed to assess the relation between CD79a<br/>expression on BM sample and overall, EFS and CNS involvement in B-cell<br/>ALL (ALL). Patients and methods: A retrospective study of expression of<br/>CD79a in 331 patients with pediatric B cell ALL, treated according to St. Jude<br/>total XV protocol at National Cancer Institute, Cairo University between<br/>January 2012 to December 2018. Results: the incidence of CNS involvement<br/>initially, there was 10 (3%) patients (CNS III),median value of CD79a<br/>expression in CNS III was as the following: 85.5 % ,MFI:140.0 MFI-ISO:<br/>128.0 MFI\ISO: 10.6 , while in (CNS I) was as the following, 42.0 % ,<br/>MFI: 74.0 , MFI-ISO:59.0, MFI\ISO:4.8. Regarding the CNS relapse, There<br/>is a strong relation between the degree of expression of CD79a in initial BM<br/>sample and the site of relapse, in isolated CNS and combined relapse showed<br/>higher level of expression of CD79a than hematological relapse. In isolated<br/>CNS relapse the median percentage of expression: 85, MFI:190,<br/>MFI\ISO:95,MFI-ISO:177,in combined relapse median percentage of<br/>expression:89,MFI:185,MFI\ISO:17.6,MFI-ISO:173 ,While hematological<br/>relapse:67,MFI:86,MFI\ISO:5.2,MFI-ISO:9.5. There is a Signiant impact of<br/>qualitative and qualitative expression of CD79a and the OS of Population<br/>who expressed percentage below(43.0) showed lower OS than patients who<br/>expressed above (43.0), P value ( <0.001), As regard MFI of expression of<br/>CD79a on initial BM sample , we have calculated it with cut point (77) the<br/>mean value of the expression on the whole cohort. It is significant impact on<br/>XII<br/>the OS , population who MFI below(77) showed lower OS than patients who<br/>expressed above (77), P value ( <0.001), As regard MFI\ISO of expression<br/>of CD79a on initial BM sample, we have calculated it with cut point (4.8) the<br/>mean value of the expression on the whole cohort. Conclusions: There is<br/>direct relation and impact on OS & EFS between quantitative CD79a on BM<br/>on CNS and site of relapse. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
سرطان الدم اللمفاوى الحاد هو اكثر انواع سرطان الاطفال شيوعا و هو الانت يشهد نسبا كبيرة من الشفاء نتيجة لتصنيف العلاج علة اساس علم الوراثة الخلوية و الجزيئية و التنميط المناعى <br/>سرطان الدم اللمفاوى الحاد مسؤول عن 25% من جميع الاورام الخبيثة لدى الاطفال و 75% من سرطان الدم لدى الاطفال |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Additional physical form available note |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Tumors in children. |
| 653 #0 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Lymphoblastic |
| -- |
CD79a |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Asmaa Mohamed Hamoda, |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Sally Talaat Khattab, |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Eman Zaghloul Kandeel, |
| Relator term |
thesis advisor. |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="http://172.23.153.220/th.pdf">http://172.23.153.220/th.pdf</a> |
| 900 ## - EQUIVALENCE OR CROSS-REFERENCE-PERSONAL NAME [LOCAL, CANADA] |
|---|
| Numeration |
01-01-2022 |
| Titles and other words associated with a name |
Asmaa Mohamed Hamoda |
| -- |
Eman Zaghloul Kandeel |
| -- |
Sally Talaat Khattab |
| Universities |
Cairo University |
| Faculties |
National Cancer Institute |
| Divisons |
Department of Pediatric Oncology |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Hanan |
| Reviser |
Essam |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |
